BGI is a pioneer in developing genomics-based solutions across the reproductive health and women's health continuum. BGI's market-leading non-invasive prenatal test (NIPT), the NIFTY® test (Non-Invasive Fetal TrisomY test), was one of the first NIPTs on the market and has been trusted by over 4 million patients worldwide to date. NIFTY® is a safe, simple, non-invasive prenatal test which offers screening for certain genetic conditions from as early as week 10 of pregnancy. Using the latest genetic sequencing technology, NIFTY® has over >99% accuracy for the three most common trisomy conditions present at birth, which are Down Syndrome, Edwards Syndrome and Patau Syndrome. To find out more about NIFTY®, please visist here.
BGI also offers a wide range of other genetic tests for Australia including VISTA™ Carrier Screening, VISTA™ PGS (Pre-implantation Genetic Screening), and VISTA™ Chromosome Sequencing. We continually seek to support and be involved in maternal and child health research in Australia.
BGI's genetic tests and diagnostic solutions are provided by BGI Genomics, an independent subsidiary under BGI Group.